CD30 immunohistochemical expression in PTCLs
| % of CD30+ tumor cells . | ALCL ALK+(N = 61) . | ALCL ALK−(N = 19) . | PTCL NOS (N = 141) . | AITL (N = 97) . | ENKTL (N = 28) . | EATL (N = 14) . | ATLL (N = 9) . | HSTL (N = 7) . |
|---|---|---|---|---|---|---|---|---|
| Score 0 | 0 | 0 | 59 | 36 | 15 | 7 | 4 | 7 |
| <5% | 42% | 37% | 53.5% | 50% | 44% | 100% | ||
| Score 1 | 0 | 0 | 37 | 46 | 2 | 0 | 1 | 0 |
| 5-24% | 26% | 47% | 7% | 11% | ||||
| Score 2 | 3 | 0 | 13 | 10 | 3 | 0 | 3 | 0 |
| 25-49% | 5% | 9% | 10% | 11% | 33% | |||
| Score 3 | 1 | 0 | 14 | 5 | 4 | 1 | 1 | 0 |
| 50-75% | 2% | 10% | 5% | 14% | 7% | 11% | ||
| Score 4 | 57 | 19 | 18 | 0 | 4 | 6 | 0 | 0 |
| >75% | 93% | 100% | 13% | 14% | 43% | |||
| Total positive cases (scores 1-4) | 61 | 19 | 82 | 61 | 13 | 7 | 5 | 0 |
| 100% | 100% | 58% | 63% | 46% | 50% | 55.5% | ||
| Strongly positive cases (scores 3-4) | 58 | 19 | 32 | 5 | 8 | 7 | 1 | 0 |
| 95.1% | 100% | 23% | 5% | 28.5% | 50% | 11% |
| % of CD30+ tumor cells . | ALCL ALK+(N = 61) . | ALCL ALK−(N = 19) . | PTCL NOS (N = 141) . | AITL (N = 97) . | ENKTL (N = 28) . | EATL (N = 14) . | ATLL (N = 9) . | HSTL (N = 7) . |
|---|---|---|---|---|---|---|---|---|
| Score 0 | 0 | 0 | 59 | 36 | 15 | 7 | 4 | 7 |
| <5% | 42% | 37% | 53.5% | 50% | 44% | 100% | ||
| Score 1 | 0 | 0 | 37 | 46 | 2 | 0 | 1 | 0 |
| 5-24% | 26% | 47% | 7% | 11% | ||||
| Score 2 | 3 | 0 | 13 | 10 | 3 | 0 | 3 | 0 |
| 25-49% | 5% | 9% | 10% | 11% | 33% | |||
| Score 3 | 1 | 0 | 14 | 5 | 4 | 1 | 1 | 0 |
| 50-75% | 2% | 10% | 5% | 14% | 7% | 11% | ||
| Score 4 | 57 | 19 | 18 | 0 | 4 | 6 | 0 | 0 |
| >75% | 93% | 100% | 13% | 14% | 43% | |||
| Total positive cases (scores 1-4) | 61 | 19 | 82 | 61 | 13 | 7 | 5 | 0 |
| 100% | 100% | 58% | 63% | 46% | 50% | 55.5% | ||
| Strongly positive cases (scores 3-4) | 58 | 19 | 32 | 5 | 8 | 7 | 1 | 0 |
| 95.1% | 100% | 23% | 5% | 28.5% | 50% | 11% |
ENKTL, extranodal natural killer/T-cell lymphoma; HSTL, hepatosplenic T-cell lymphoma.